PLVAP and neoplasm: We reasoned that infusion of anti-PLVAP Fab-TF into the tumor feeding artery would provide a saturating concentration of anti-PLVAP Fab for binding to the target antigen and reduce the amount of Fab-TF required to achieve therapeutic effect through systemic administration.